Tiziana Life Sciences (NASDAQ:TLSA) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Volatility and Risk

Tiziana Life Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Tiziana Life Sciences and Vanda Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences 0 0 1 0 3.00
Vanda Pharmaceuticals 1 1 2 0 2.25

Tiziana Life Sciences presently has a consensus target price of $20.00, suggesting a potential upside of 257.78%. Vanda Pharmaceuticals has a consensus target price of $16.00, suggesting a potential upside of 39.62%. Given Tiziana Life Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe Tiziana Life Sciences is more favorable than Vanda Pharmaceuticals.

Insider & Institutional Ownership

4.9% of Tiziana Life Sciences shares are held by institutional investors. Comparatively, 98.6% of Vanda Pharmaceuticals shares are held by institutional investors. 8.2% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Tiziana Life Sciences and Vanda Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tiziana Life Sciences N/A N/A -$7.99 million N/A N/A
Vanda Pharmaceuticals $227.19 million 2.75 $115.55 million $2.11 5.43

Vanda Pharmaceuticals has higher revenue and earnings than Tiziana Life Sciences.

Profitability

This table compares Tiziana Life Sciences and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tiziana Life Sciences N/A N/A N/A
Vanda Pharmaceuticals 49.12% 30.60% 25.65%

Summary

Vanda Pharmaceuticals beats Tiziana Life Sciences on 8 of the 11 factors compared between the two stocks.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.